What did the FDA approve Rybrevant Faspro for on November 5, 2026?

The FDA granted accelerated approval on November 5, 2026 to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and anti-PD-(L)1 therapy. In OrigAMI-4 (102 patients) the response rate was 42%, and 56% of responders kept responses for at least 6 months; a Phase 3 trial, OrigAMI-5, must still confirm real clinical benefit. HPV-associated oropharyngeal cancer is excluded.

What happened, stated plainly: on November 5, 2026, the U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease had progressed after platinum-based chemotherapy and anti-PD-(L)1 therapy. The approval does not cover HPV-associated oropharyngeal cancer.The evidence behind it: in the OrigAMI-4 trial, 102 patients received the treatment and the overall response rate was 42 percent — meaning tumours shrank or disappeared in about four in ten patients.

Among those who responded, 56 percent had responses lasting at least six months.What “accelerated approval” means in plain English: normally, the FDA waits for proof that a drug helps patients live longer or feel better before approving it. Under accelerated approval, the agency lets a treatment for a serious condition reach patients sooner, based on an earlier measure — here, how many tumours shrank — that it judges reasonably likely to predict real benefit. The trade-off is that the benefit is not yet proven.Why the OrigAMI-5 trial matters: OrigAMI-5 is the Phase 3 confirmatory trial the FDA requires to verify that shrinking tumours actually translates into clinical benefit, such as longer survival.

If it confirms benefit, the approval can become a regular one. If it fails to confirm benefit, the FDA can require the drug to be withdrawn for this use — accelerated approvals have been pulled before when confirmatory trials came up short. Until OrigAMI-5 reads out, a response in a trial is not the same as longer life.Questions to ask your oncologist: Am I in the exact group this was approved for, including the HPV exclusion?

What side effects should I expect, and how would they be managed? What other options — including clinical trials — should I compare it against? And if the confirmatory trial changes the picture, what happens to my treatment plan?

This is an additional option for patients whose standard treatments had already stopped working; it is not a proven cure.Pro tip: do not mistake accelerated approval for proof that a drug extends life. Before treating it as settled science, ask whether the confirmatory-trial results are out yet — that answer changes how much weight the approval deserves.